Home Technology Seminars

Technology Seminar (21 Aug 2014)

Print

Technology Seminar

21 August 2014 (Thursday)

Seminar Room 2, G/F
The Hong Kong Jockey Club Building for Interdisciplinary Research
5 Sassoon Road, Pokfulam, Hong Kong


Mr Jin Ngee

Regional Application Specialist


10:15 – 11:15am
PrimeTime® 5’–Nuclease qPCR Assay: An introduction
 
Abstract:

5’–Nuclease qPCR assays depend on biased signal generation. This signal generation is dependent on the efficiency of quenching from the quencher. Efficient quenching is dependent on the proximity of the quencher to the reporter. IDT achieves this by placing a quencher between the 9th and 10th base from the reporter. In other schemes which use a Tm enhancer such as MGB, IDT’s approach maintains the same freedom of design for DNA probes that will otherwise be rendered inefficient when using sequences designed to be enhanced with MGB. Detailed in this presentation is the performance of the Zen double-quenched probe setup compares with an internal BHQ1-dT setup.

 
&
11:30am – 12:30pm
Target capture with xGen® oligonucleotide probes for NGS
 
Abstract:

Genomic target selection enables faster development of clinical sequencing tests for disease diagnosis, stratification, and informed therapy selection by allowing smaller, specific regions of the genome to be sequenced and analyzed at high depth in a cost-effective manner. Faster, targeted sequencing could also accelerate development of effective therapies for various diseases. Current available commercial target capture reagents use biotinylated, array-synthesized oligonucleotides to generate DNA or RNA probes, often referred to as “baits”. However, baits that are generated by these methods often present performance challenges. IDT has developed an improved bait synthesis methodology known as xGen® Lockdown® Probes that meet those challenges. Based on the superior performance of these IDT has launched two hybridization enrichment panels. The first targets the documented genes that are associated with Acute Myeloid Leukemia (AML) and the second is based the Inherited Disease Panel which is based on the HGMD® (Human Gene Mutation Database). Presented will be data documenting the probes’ performance, an improved target capture protocol that has been validated with a target capture panel.

 

ALL ARE WELCOME


Co-organized with Integrated DNA Technologies (IDT) Inc. Integrated DNA Technologies (IDT) Inc
Refreshment to be served
For enquiries, please call 2831-5500 or write to This e-mail address is being protected from spambots. You need JavaScript enabled to view it